RxDoctor Payments Data

Patrick Reme, MD

Infectious Disease · Plantation, FLNPI 1649265067

Payments from drug & device makers

$1,567in general payments, 2019–2025

Across 55 payments — averaging $28.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$419
  • AbbVie$195
  • Gilead$162
  • Insmed, Inc.$144
  • Angiodynamics, Inc.$143
  • Merck$114
  • plus $390 from 8 others

What the payments were for

  • Food & beverage$1,37087%
  • Education$19613%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,567 in reported general payments places this provider in the 55th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$172,451
Medicare patients
298
Services billed
1,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala244$949,468
GenvoyaElviteg/Cob/Emtri/Tenof Alafen81$288,962
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf55$252,573
OdefseyEmtricitab/Rilpiviri/Tenof Ala66$239,484
CabenuvaCabotegravir/Rilpivirine24$178,930
TriumeqAbacavir/Dolutegravir/Lamivudi44$155,416
JulucaDolutegravir/Rilpivirine32$106,911
DovatoDolutegravir Sodium/Lamivudine36$100,749
PrezcobixDarunavir/Cobicistat39$94,935
DescovyEmtricitabine/Tenofov Alafenam21$44,885
TivicayDolutegravir Sodium16$35,572
ErtapenemErtapenem Sodium36$24,436
Meropenem19$11,951
Daptomycin13$10,437
Vancomycin Hcl41$7,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$162$1,283,315346 claims
Viiv Healthcare CompanyCabenuva, Triumeq, Juluca, Dovato, Tivicay$419$577,578152 claims
Janssen Products, LPSymtuza$99$252,57355 claims
Johnson & JohnsonPrezcobix$57$94,93539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →